Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Table S1: Baseline Characteristics.Table S2: Treatment Effects – First Line.Table S3: Adverse Events.Table S4: Treatment effects for second/third line treatments (treatment policy estimand).Table S5: Proportion of patients on preventive medication.Table S6: Screening and patient management proportions.Table S7: Sensitivity and specificity of tests.Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).Table S10: Utilities used in CDM.Table S11: Scenario analysis results.Table S12: Breakdown of costs (DKK, per average patient)

Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Table S1: Baseline Characteristics.Table S2: Treatment Effects – First Line.Table S3: Adverse Events.Table S4: Treatment effects for second/third line treatments (treatment policy estimand).Table S5: Proportion of patients on preventive medication.Table S6: Screening and patient management proportions.Table S7: Sensitivity and specificity of tests.Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).Table S10: Utilities used in CDM.Table S11: Scenario analysis results.Table S12: Breakdown of costs (DKK, per average patient)

Appendix A: Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder.docx

Appendix A – Model Assumptions and Parameter Summar